Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)

Tongji University

Status: Not yet enrolling

Conditions: Lung Cancer

Treatments: Other: The investigators will extract total protein, DNA and RNA from PSC patients.

Study type: Observational

Funder types: Other

Identifiers

NCT04215913

2019-FD52Rainy-PSC

FD52Rainy (Registry Identifier)

Details and patient eligibility

About

Integrative Analysis of pulmonary sarcomatoid carcinoma (PSC)

Full description

The investigators will analyzed proteomes of paired normal lung tissues and pulmonary sarcomatoid carcinoma with or without metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary pulmonary sarcomatoid carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≤ 70 years with histologically proven LCLC
• No severe major organ dysfunction
• World Health Organization (WHO) performance status of 0 or 1
• No prior cancer chemotherapy

Exclusion criteria

• Age ≥ 70
• Severe major organ dysfunction
• WHO performance status of >1
• Prior cancer chemotherapy

Trial design

300 participants in 3 patient groups

Normal lung tissue

Description:

Normal lung tissue from PSC patients

Treatment:

Other: The investigators will extract total protein, DNA and RNA from PSC patients.

PSC tissues

Description:

PSC tissues from PSC patients

Treatment:

Other: The investigators will extract total protein, DNA and RNA from PSC patients.

Metastasis tissues

Description:

Metastasis tissues from PSC patients

Treatment:

Other: The investigators will extract total protein, DNA and RNA from PSC patients.